Conavi Medical Corp. Announces Filing of Amended & Restated Final Prospectus

Executive Summary

• Conavi Medical Corp. announced the filing of an amended and restated final short‑form prospectus for a public offering of common shares and pre‑funded warrants.
• The offering targets 26.7 million to 33.3 million securities at $0.45 per share (or $0.44999 per warrant), aiming to raise $12 M–$15 M in gross proceeds.
• Net proceeds will be used to obtain FDA 510(k) clearance for the next‑generation Novasight Hybrid system, fund a U.S. market release, and support working capital/general corporate purposes.

Key Details

• Securities Offered: Minimum 26,666,667 and maximum 33,333,333 common shares and/or pre‑funded warrants.
• Pricing: $0.45 per common share; $0.44999 per pre‑funded warrant (exercise price $0.00001 per share).
• Gross Proceeds Target: $12 M to $15 M.
• Use of Proceeds:
• Obtain U.S. FDA 510(k) clearance for next‑generation Novasight Hybrid system.
• Complete targeted market release in the United States.
• Working capital and other general corporate purposes.
• Offering Structure: Conducted on a commercially reasonable efforts agency basis via Bloom Burton Securities Inc.; may be completed in one or more tranches.
• Closing Timeline: Initial closing expected on or about January 13, 2026, subject to customary conditions and regulatory approvals (TSXV, etc.).
• Agent Compensation:
• Cash fee equal to 6.5% of gross proceeds (reduced to 3.25% for securities sold to certain “president’s list” purchasers).
• Grant of compensation options equal to 6.5% of the aggregate number of securities issued, exercisable at the offering price; no options for president’s‑list sales. Options expire 24 months after closing date.
• Regulatory Filings: Amended & restated final short‑form prospectus filed on Jan 7 2026 with Alberta, BC, and Ontario securities regulators; will be accessible on SEDAR+. No sale of securities until receipt of the A&R Final Prospectus is issued.
• Private Placement Component: Securities may also be offered via private placement in jurisdictions outside Canada, complying with local securities laws.

Notable Quotes

(No executive quotes were included in the release.)